510(k) quality review will include team analysis of selected SE/NSE decisions -- FDA memo.
This article was originally published in The Gray Sheet
Executive Summary
510(K) DECISION QUALITY REVIEW BY CDRH PANELS will be conducted under "blue book" memo I96-1, issued March 29 by the Office of Device Evaluation of FDA's Center for Devices and Radiological Health. The memo outlines a general framework for a revised 510(k) quality review program, which will include the establishment of quality review teams charged with reviewing random samples of substantially and not substantially equivalent 510(k)s from each of ODE's 18 branches.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.